RATIONALE: HIV-1-induced interstitial pneumonitis (IP) is a serious complication of HIV-1 infection, characterized by inflammation and cellular infiltration in lungs, often leading to respiratory failure and death. The barrier function of the pulmonary endothelium is caused in part by tight junction (TJ) proteins, such as claudin-5. Peroxisome proliferator-activated receptor (PPAR)-γ is expressed in lung tissues and regulates inflammation. We hypothesize that HIV-1 induces vascular lung injury, and HIV-1-mediated damage of the pulmonary endothelium and IP is associated with dysregulation of PPAR-γ. OBJECTIVES: Investigate the effects of HIV-1 infection on the pulmonary microvasculature and the modulatory effects of the PPAR-γ ligands. METHODS: Using human lung tissues, we demonstrated down-regulation of claudin-5 (marker of pulmonary barrier integrity), down-regulation of PPAR-γ transcription, and expression in lung tissues of HIV-1-infected humans with IP. MEASUREMENTS AND MAIN RESULTS: Human lung microvascular endothelial cells expressed the TJ proteins claudin-5, ZO-1, and ZO-2; HIV-1 decreased TJ proteins expression and induced nuclear factor-κB promoter activity, which was reversed by PPAR-γ agonist. Using two murine HIV/AIDS models, we demonstrated decreased claudin-5 expression and increased macrophage infiltration in the lungs of HIV-1-infected animals. Activation of PPAR-γ prevented HIV-1-induced claudin-5 down-regulation and significantly reduced viremia and pulmonary macrophage infiltration. CONCLUSIONS: HIV-induced IP is associated with injury to the lung vascular endothelium, with decreased TJ and PPAR-γ expression, and increased pulmonary macrophage infiltration. PPAR-γ ligands abrogated these effects. Thus, regulation of PPAR-γ can be a therapeutic approach against HIV-1-induced vascular damage and IP in infected humans. Removal of Expression of Concern: Issues leading to the previous expression of concern for this article have been resolved after further revisions and editorial review. No further concerns exist.
RATIONALE: HIV-1-induced interstitial pneumonitis (IP) is a serious complication of HIV-1 infection, characterized by inflammation and cellular infiltration in lungs, often leading to respiratory failure and death. The barrier function of the pulmonary endothelium is caused in part by tight junction (TJ) proteins, such as claudin-5. Peroxisome proliferator-activated receptor (PPAR)-γ is expressed in lung tissues and regulates inflammation. We hypothesize that HIV-1 induces vascular lung injury, and HIV-1-mediated damage of the pulmonary endothelium and IP is associated with dysregulation of PPAR-γ. OBJECTIVES: Investigate the effects of HIV-1 infection on the pulmonary microvasculature and the modulatory effects of the PPAR-γ ligands. METHODS: Using human lung tissues, we demonstrated down-regulation of claudin-5 (marker of pulmonary barrier integrity), down-regulation of PPAR-γ transcription, and expression in lung tissues of HIV-1-infectedhumans with IP. MEASUREMENTS AND MAIN RESULTS:Human lung microvascular endothelial cells expressed the TJ proteins claudin-5, ZO-1, and ZO-2; HIV-1 decreased TJ proteins expression and induced nuclear factor-κB promoter activity, which was reversed by PPAR-γ agonist. Using two murine HIV/AIDS models, we demonstrated decreased claudin-5 expression and increased macrophage infiltration in the lungs of HIV-1-infected animals. Activation of PPAR-γ prevented HIV-1-induced claudin-5 down-regulation and significantly reduced viremia and pulmonary macrophage infiltration. CONCLUSIONS: HIV-induced IP is associated with injury to the lung vascular endothelium, with decreased TJ and PPAR-γ expression, and increased pulmonary macrophage infiltration. PPAR-γ ligands abrogated these effects. Thus, regulation of PPAR-γ can be a therapeutic approach against HIV-1-induced vascular damage and IP in infected humans. Removal of Expression of Concern: Issues leading to the previous expression of concern for this article have been resolved after further revisions and editorial review. No further concerns exist.
Authors: Y Persidsky; J Limoges; R McComb; P Bock; T Baldwin; W Tyor; A Patil; H S Nottet; L Epstein; H Gelbard; E Flanagan; J Reinhard; S J Pirruccello; H E Gendelman Journal: Am J Pathol Date: 1996-09 Impact factor: 4.307
Authors: Joseph T Crossno; Chrystelle V Garat; Jane E B Reusch; Kenneth G Morris; Edward C Dempsey; Ivan F McMurtry; Kurt R Stenmark; Dwight J Klemm Journal: Am J Physiol Lung Cell Mol Physiol Date: 2006-12-22 Impact factor: 5.464
Authors: Salvatore Cuzzocrea; Barbara Pisano; Laura Dugo; Angela Ianaro; Pasquale Maffia; Nimesh S A Patel; Rosanna Di Paola; Armando Ialenti; Tiziana Genovese; Prabal K Chatterjee; Massimo Di Rosa; Achille P Caputi; Christoph Thiemermann Journal: Eur J Pharmacol Date: 2004-01-01 Impact factor: 4.432
Authors: Shashi Shrivastav; Tomoshige Kino; Tshaka Cunningham; Takamasa Ichijo; Ulrich Schubert; Peter Heinklein; George P Chrousos; Jeffrey B Kopp Journal: Mol Endocrinol Date: 2007-10-11
Authors: Andrea Peter; Diana Fatykhova; Olivia Kershaw; Achim D Gruber; Jens Rueckert; Jens Neudecker; Mario Toennies; Torsten T Bauer; Paul Schneider; Maria Schimek; Stephan Eggeling; Norbert Suttorp; Andreas C Hocke; Stefan Hippenstiel Journal: Histochem Cell Biol Date: 2017-03-01 Impact factor: 4.304
Authors: Byeong Gon Kim; Pureun Haneul Lee; Sun Hye Lee; Ae Rin Baek; Jong Sook Park; Junehyuk Lee; Sung Woo Park; Do Jin Kim; Choon Sik Park; An Soo Jang Journal: Allergy Asthma Immunol Res Date: 2018-09 Impact factor: 5.764